FMR LLC reported beneficial ownership of 4,577,262 shares of Odyssey Therapeutics Inc common stock, representing 10.2% of the class as disclosed on the form. The filing lists sole voting and sole dispositive power over the 4,577,262 shares and names Abigail P. Johnson in related disclosures.
Odyssey Therapeutics, Inc. Schedule 13G shows that Lightspeed-affiliated entities report beneficial ownership of 3,608,443 shares of Odyssey Therapeutics common stock. The filing states this equals 7.6% of the class based on 47,174,156 shares outstanding as of May 11, 2026.
The report lists shared voting and dispositive power for the Lightspeed entities and is filed jointly by Lightspeed Venture Partners XV-B (Ignite), L.P., Lightspeed General Partner XV-B (Ignite), L.P., and Lightspeed Ultimate General Partner XV-B (Ignite), L.L.C.
SR One-affiliated funds filed a Schedule 13D reporting beneficial ownership of 3,794,883 shares of Odyssey Therapeutics common stock, representing 8.0% of the company. The stake is held across SR One Fund I Aggregator, SR One Co-Invest vehicles and AMZL, all controlled through SR One Capital Management and ultimately by Dr. Simeon George.
The position arose from Odyssey’s initial public offering of 15,500,000 shares at $18.00 per share and the automatic conversion of multiple preferred stock series and warrants into common stock immediately before the IPO closing. The filing states the investment is for investment purposes, with no current plans for corporate changes.
The funds have registration rights under an Investors' Rights Agreement, including demand and piggyback rights, and are subject to a 180-day lock-up from May 7, 2026 that restricts sales, hedging and registration demands during that period.
TPG-affiliated investors have disclosed a significant new stake in Odyssey Therapeutics, Inc. Funds managed through TPG GP A, LLC now beneficially own 3,690,146 shares of Odyssey common stock, representing about 7.8% of the 47,174,156 shares outstanding as of the IPO closing.
The position includes 1,388,889 shares that TPG LSI Rise Orazio II, L.P. bought directly from Odyssey for $25,000,002 in a concurrent private placement at $18.00 per share, matching the initial public offering price. An Investors' Rights Agreement grants registration rights for resale of these shares, and the filing notes TPG may later consider actions involving Odyssey's operations, capital structure or additional share transactions.
Odyssey Therapeutics, Inc. insider Jolie Siegel reported existing derivative holdings on a Form 3. The filing shows a stock option to buy common stock with an exercise price of $5.15 per share for 78,958 underlying shares, expiring on March 11, 2036. According to the vesting terms, 25% of this option will vest on January 12, 2027, with the rest vesting in 36 equal monthly installments, contingent on continued service.